Health News

Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

Author: Australian Business

PARIS and TARRYTOWN, N.Y., Oct. 16, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9......

More...

More Articles...

New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis
Implementation of Quality by Design Set to Steer the Pharmaceutical Industry in the Region
Obamacare is Free -- for Americans with a Spare $3.4 Million
X-Runner™ - World's First All Tissue Ablative Laser Scanning Handpiece for Dentistry
Medbox and Its Clients Benefit From Another Huge Arizona Court Ruling
iBio, Inc. Announces Temporary Reduction in Exercise Price of Certain Warrants
Medbox Partnership with Canadian R D Laboratory will Benefit its US Clients
La Latino Commission on AIDS suma esfuerzos con la actriz/modelo Dayana Mendoza para promover la realización de pruebas de VIH con ocasión del National Latino AIDS Awareness Day
Branchenbericht verdeutlicht 6 höchste Prioritäten von IT- und Management-Führungskräften im Gesundheitswesen
Child Passenger Safety Statistics You Should Know

Page 894 of 1906